2-[1-(4-hydroxyphenyl)ethyl]-1H-isoindole-1,3(2H)-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[1-(4-hydroxyphenyl)ethyl]-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-[1-(4-hydroxyphenyl)ethyl]isoindole-1,3-dione
• 化学式: C₁₆H₁₃NO₃
• 分子量: 267.28
• InChiKey: UDPXIRYLKKQVBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS<br/>[FR] COMPOSÉS DE PYRIMIDINE-DIONE CONTRE LES AFFECTIONS CARDIAQUES
  申请人：MYOKARDIA INC

  公开号：WO2014205223A1

  公开（公告）日：2014-12-24

  Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

  提供了新型嘧啶二酮化合物及其药用盐，可用于治疗肥厚型心肌病（HCM）和与左心室肥厚或舒张功能障碍相关的病症。描述了这些化合物及其药用盐的合成和表征，以及治疗HCM和其他形式心脏疾病的方法。
• PYRIMIDINEDIONE COMPOUNDS
  申请人：MYOKARDIA, INC.

  公开号：US20170281626A1

  公开（公告）日：2017-10-05

  Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

  提供了新型嘧啶二酮化合物及其药学上可接受的盐，可用于治疗肥厚型心肌病（HCM）和与左心室肥厚或舒张功能障碍有关的疾病。描述了该化合物及其药学上可接受的盐的合成和表征，以及治疗HCM和其他形式心脏疾病的方法。
• PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS
  申请人：MyoKardia, Inc.

  公开号：EP3702352A1

  公开（公告）日：2020-09-02

  Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

  本文提供了新型嘧啶二酮化合物及其药学上可接受的盐类，可用于治疗肥厚型心肌病（HCM）以及与左心室肥大或舒张功能障碍相关的疾病。本文描述了这些化合物及其药学上可接受的盐的合成和表征，以及治疗 HCM 和其他形式心脏病的方法。
• Method for producing a heterocyclic compound and an aromatic carboxylic acid having one or more hydroxyl groups, and modified aromatic ring dioxygenase
  申请人：——

  公开号：US20040086983A1

  公开（公告）日：2004-05-06

  An objective of the present invention is to provide a method of producing hydroxylated heterocyclic compounds and hydroxylated aromatic carboxylic acids by bioengineering technique, and modified enzymes which can be used for this method. A method of producing hydroxylated heterocyclic compounds or hydroxylated aromatic carboxylic acids comprises reacting an aromatic ring dioxygenase with heterocyclic compounds or aromatic carboxylic acids to hydroxylate these compounds. An enzyme according to the present invention is an aromatic ring dioxygenase comprising an &agr;-subunit consisting of the amino acid sequence of SEQ ID NO: 2, which is modified according to the &agr;-subunit of the biphenyl dioxygenase derived from the strain Burkholderia cepacia LB400, a &bgr;-subunit consisting of the amino acid sequence of SEQ ID NO: 4, and a ferredoxin consisting of the amino acid sequence of SEQ ID NO: 6, and a ferredoxin reductase consisting of the amino acid sequence of SEQ ID NO: 8.

  本发明的目的是提供一种通过生物工程技术生产羟基化杂环化合物和羟基化芳香族羧酸的方法，以及可用于该方法的改良酶。生产羟基化杂环化合物或羟基化芳香族羧酸的方法包括使芳香环二加氧酶与杂环化合物或芳香族羧酸反应，使这些化合物羟基化。根据本发明的一种酶是一种芳香环二加氧酶，它包括一个由 SEQ ID NO: 2 的氨基酸序列组成的&agr;-亚基，它是根据从菌株中得到的联苯二加氧酶的&agr;-亚基修饰的 伯克霍尔德氏菌 LB400，由 SEQ ID NO: 4 的氨基酸序列组成的&bgr;-亚基，由 SEQ ID NO: 6 的氨基酸序列组成的铁毒素，以及由 SEQ ID NO: 8 的氨基酸序列组成的铁毒素还原酶。
• PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS
  申请人：MyoKardia, Inc.

  公开号：EP3010910B1

  公开（公告）日：2020-02-05